Business Description
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Business History
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -1.04
Total Equity: $94.39M
Shares: 29,422,221
Total Debt: $692,000
Cash: $52.77M
EBITDA: -$32.25M
Total Debt: $692,000
Cash: $52.77M
Revenue: $917,000
Shares: 29,422,221
Revenue: $917,000
Revenue: $917,000
Revenue: $917,000
Total Equity: $94.39M
Tax Rate: 7.7%
Equity: $94.39M
Total Debt: $692,000
Cash: $52.77M
Current Liabilities: $11.60M
Long-Term Debt: $78,000
Total Debt: $692,000
Total Equity: $94.39M
Shares: 29,422,221
Shares: 29,422,221
CapEx: -$4,000
Shares: 29,422,221
Stock Price: $2.76
Net Income: -$30.52M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 24, 2026 3:15am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $802,000 | $410,000 | $279,000 | $637,000 | $917,000 |
| Cost of Revenue | $70,000 | $0 | $0 | $154,000 | $422,000 |
| Gross Profit | $802,000 | $410,000 | $279,000 | $483,000 | $495,000 |
| Operating Expenses | $29.0M | $60.9M | $15.3M | $103.1M | $26.6M |
| Operating Income | -$21.2M | -$60.5M | -$15.0M | -$102.6M | -$26.1M |
| Net Income | -$24.5M | -$124.7M | -$1.9M | -$34.4M | -$30.5M |
| EBITDA | -$23.3M | -$139.9M | -$8.7M | -$66.8M | -$32.3M |
| EPS | $-1.47 | $-6.31 | $-0.08 | $-1.45 | $-1.04 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 3:15am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $7.9M | $26.5M | $21.5M | $2.7M | $52.8M |
| Total Current Assets | $14.8M | $108.3M | $82.9M | $72.5M | $56.7M |
| Total Assets | $154.1M | $118.3M | $98.8M | $96.8M | $114.1M |
| Current Liabilities | $17.3M | $21.0M | $2.1M | $7.5M | $11.6M |
| Long-Term Debt | $0 | $0 | $0 | $73,000 | $78,000 |
| Total Liabilities | $17.4M | $21.1M | $2.2M | $10.6M | $15.7M |
| Total Equity | $122.3M | $100.5M | $100.3M | $82.2M | $94.4M |
| Retained Earnings | -$40.8M | -$165.5M | -$167.3M | -$201.7M | -$232.3M |
Cash Flow (Annual)
Last updated: Jun 24, 2026 3:15am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$15.6M | -$26.1M | -$10.9M | -$7.8M | -$18.9M |
| Capital Expenditure | $-206,000 | $-2,000 | $51.7M | $-178,000 | $-4,000 |
| Free Cash Flow | -$15.8M | -$26.1M | $40.8M | -$8.0M | -$18.9M |
| Acquisitions (net) | $4.6M | $0 | -$5.1M | $2.4M | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $-218,000 | $-168,000 | $0 |
| Net Change in Cash | $6.6M | $13.7M | -$5.0M | -$18.8M | $50.1M |
Growth Trends (YoY %)
Last updated: Jun 24, 2026 3:15am (3d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -48.9% | -32.0% | +128.3% | +44.0% |
| Gross Profit Growth | -48.9% | -32.0% | +73.1% | +2.5% |
| Operating Income Growth | -185.3% | +75.1% | -582.2% | +74.6% |
| Net Income Growth | -407.9% | +98.5% | -1,734.2% | +11.3% |
| EBITDA Growth | -499.3% | +93.8% | -670.6% | +51.7% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 4:47am (5h ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-21 | Polinsky David | F-InKind | 2,386.00 | $2.64 | $6,287 |
| 2026-06-13 | JONAS HOWARD S | A-Award | 142,857.00 | $1.75 | $250,000 |
| 2026-06-13 | JONAS HOWARD S | F-InKind | 8,786.00 | $2.33 | $20,471 |
| 2026-03-21 | Polinsky David | F-InKind | 2,318.00 | $1.28 | $2,955 |
| 2026-03-13 | JONAS HOWARD S | F-InKind | 9,826.00 | $1.50 | $14,764 |
| 2026-01-28 | Sieger Markus | A-Award | 29,528.00 | $1.27 | $37,501 |
| 2026-01-28 | WEISS MICHAEL J | A-Award | 39,370.00 | $1.27 | $50,000 |
| 2026-01-28 | STEIN MARK N | A-Award | 39,370.00 | $1.27 | $50,000 |
| 2026-01-28 | GRAYSON ALAN | A-Award | 6,562.00 | $1.27 | $8,334 |
| 2026-01-13 | JONAS HOWARD S | A-Award | 75,000.00 | $1.25 | $93,638 |
| 2026-01-13 | Polinsky David | A-Award | 50,000.00 | $1.25 | $62,425 |
| 2026-01-13 | Polinsky David | F-InKind | 4,865.00 | $1.25 | $6,074 |
| 2025-12-21 | Polinsky David | F-InKind | 1,961.00 | $1.29 | $2,520 |
| 2025-12-13 | JONAS HOWARD S | F-InKind | 9,867.00 | $1.50 | $14,776 |
| 2025-10-23 | GRAYSON ALAN | 0.00 | $0.00 | $0 | |
| 2025-10-25 | Polinsky David | F-InKind | 4,180.00 | $1.35 | $5,643 |
| 2025-09-23 | Polinsky David | F-InKind | 1,284.00 | $1.48 | $1,900 |
| 2025-09-21 | Polinsky David | F-InKind | 1,970.00 | $1.49 | $2,935 |
| 2025-09-13 | JONAS HOWARD S | F-InKind | 9,905.00 | $1.35 | $13,322 |
| 2025-09-03 | Fine Joshua M | A-Award | 24,558.00 | $1.38 | $33,890 |
Dividend History (Last 20)
Last updated: Jun 24, 2026 3:15am (3d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2009-12-18 | $0.02 | 2009-12-31 | ||
| 2009-06-19 | $0.02 | 2009-06-19 | 2009-06-30 |
Narrative Economics
market-narrative step).